Melatonin, environmental light, and breast cancer

Breast Cancer Research and Treatment

Volumn 108, Issue 3, 2008, Pages 339-350

  Srinivasan, V ^a   Spence, D W ^b   Pandi Perumal, S R ^c   Trakht, I ^c   Esquifino, A I ^d   Cardinali, D P ^e   Maestroni, G J ^f  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b Sleep and Neuropsychiatry Institute   (Canada)

^c College of Physicians and Surgeons of Columbia University ^*  (United States)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^f INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Breast cancer; Estrogen receptor; Light at night; Meditation; Melatonin; Melatonin receptors; Shift work

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ESTROGEN RECEPTOR ALPHA; MELATONIN; METHYLNITROSOUREA;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CELL STRAIN MCF 7; HUMAN; HUMAN CELL; LIGHT; MEDITATION; METASTASIS; PRIORITY JOURNAL; REVIEW; SHIFT WORKER;

BREAST NEOPLASMS; CIRCADIAN RHYTHM; FEMALE; HUMANS; LIGHT; LIGHTING; MELATONIN; OCCUPATIONAL EXPOSURE;

EID: 41149179969     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9617-5     Document Type: Review

References (145)

1. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8):S4-S66
2. Smigal C, Jemal A, Ward E et al (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168-183
3. Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133-140
4. Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6:213-218
5. Russo J, Hasan LM, Balogh G, Guo S, Russo IH (2003) Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 87:1-25
6. Yue W, Santen RJ, Wang JP et al (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86:477-486
7. Anisimov VN (2003) The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 46:221-234
8. Jasser SA, Blask DE, Brainard GC (2006) Light during darkness and cancer: relationships in circadian photoreception and tumor biology. Cancer Causes Control 17:515-523
9. Rajaratnam SM, Arendt J (2001) Health in a 24-h society. Lancet 358:999-1005
10. Stevens RG (1987) Electric power use and breast cancer: a hypothesis. Am J Epidemiol 125:556-561
11. Stevens RG (2005) Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 16:254-258
12. Stevens RG (2006) Artificial lighting in the industrialized world: circadian disruption and breast cancer. Cancer Causes Control 17:501-507
13. Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE (2004) Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev 13:936-943
14. Travis RC, Allen DS, Fentiman IS, Key TJ (2004) Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 96:475-482
15. Bartsch C, Bartsch H (2006) The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies. Cancer Causes Control 17:559-571
16. Hill SM, Ram PT, Molis TM, Spriggs LL (1998) Melatonin at the neoplastic cellular level. In: Shaffi M, Shaffi SL (eds) Melatonin in psychiatric and neoplastic disorders. American Psychiatric Press Inc., Washington DC, pp. 191-241
17. Reiter RJ (1991) Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 79:C153-C158
18. Vollrath L (1979) Comparative morphology of the vertebrate pineal complex. Prog Brain Res 52:25-38
19. Macchi MM, Bruce JN (2004) Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 25:177-195
20. Cardinali DP, Nagle CA, Denari JH, Bedes GDP, Rosner JM (1973) Lack of effects of light on the rat pineal in organ culture. Gen Comp Endocrinol 21:573-577
21. Huang SK, Klein DC, Korf HW (1992) Immunocytochemical demonstration of rod-opsin, S-antigen, and neuron-specific proteins in the human pineal gland. Cell Tissue Res 267:493-498
22. Cardinali DP, Rosner JM (1971) Retinal localization of hydroxyindole-O-methyl transferase (HIOMT) in the rat. Endocrinology 89:301-303
23. Tosini G, Menaker M (1998) The clock in the mouse retina: melatonin synthesis and photoreceptor degeneration. Brain Res 789:221-228
24. Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP (2006) Role of melatonin in the eye and ocular dysfunctions. Vis Neurosci 23(6):853-862
25. Slominski A, Fischer TW, Zmijewski MA et al (2005) On the role of melatonin in skin physiology and pathology. Endocrine 27:137-148
26. Raikhlin NT, Kvetnoy IM (1976) Melatonin and enterochromaffine cells. Acta Histochem 55:19-24
27. Bubenik GA (2002) Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 47:2336-2348
28. Carrillo-Vico A, Calvo JR, Abreu P et al (2004) Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 18:537-539
29. Champier J, Claustrat B, Besancon R et al (1997) Evidence for tryptophan hydroxylase and hydroxy-indol-O-methyl-transferase mRNAs in human blood platelets. Life Sci 60:2191-2197
30. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM (2000) Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 28:193-202
31. Liu T, Borjigin J (2005) N-acetyltransferase is not the rate-limiting enzyme of melatonin synthesis at night. J Pineal Res 39:91-96
32. Tricoire H, Moller M, Chemineau P, Malpaux B (2003) Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod Suppl 61:311-321
33. Cardinali DP, Pevet P (1998) Basic aspects of melatonin action. Sleep Med Rev 2:175-190
34. Claustrat B, Brun J, Chazot G (2005) The basic physiology and pathophysiology of melatonin. Sleep Med Rev 9:11-24
35. Arendt J, Wirz-Justice A, Bradtke J, Kornemark M (1979) Long-term studies on immunoreactive human melatonin. Ann Clin Biochem 16:307-312
36. Bergiannaki JD, Soldatos CR, Paparrigopoulos TJ, Syrengelas M, Stefanis CN (1995) Low and high melatonin excretors among healthy individuals. J Pineal Res 18:159-164
37. Griefahn B, Brode P, Remer T, Blaszkewicz M (2003) Excretion of 6-hydroxymelatonin sulfate (6-OHMS) in siblings during childhood and adolescence. Neuroendocrinology 78:241-243
38. Skene DJ, Papagiannidou E, Hashemi E et al (2001) Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J Pineal Res 31:333-342
39. Hirata F, Hayaishi O, Tokuyama T, Seno S (1974) In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 249:1311-1313
40. Hardeland R, Reiter RJ, Poeggeler B, Tan DX (1993) The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 17:347-357
41. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007) One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 42:28-42
42. Moore RY (1996) Neural control of the pineal gland. Behav Brain Res 73:125-130
43. Brainard GC, Hanifin JP, Greeson JM et al (2001) Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 21:6405-6412
44. Berson DM, Dunn FA, Takao M (2002) Phototransduction by retinal ganglion cells that set the circadian clock. Science 295:1070-1073
45. Brainard GC, Hanifin JP, Rollag MD et al (2001) Human melatonin regulation is not mediated by the three cone photopic visual system. J Clin Endocrinol Metab 86:433-436
46. Panda S, Sato TK, Castrucci AM et al (2002) Melanopsin (Opn4) requirement for normal light-induced circadian phase shifting. Science 298:2213-2216
47. Burgoon PW, Lindberg PT, Gillette MU (2004) Different patterns of circadian oscillation in the suprachiasmatic nucleus of hamster, mouse, and rat. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 190:167-171
48. Gonzalez Burgos G, Rosenstein RE, Cardinali DP (1994) Daily changes in presynaptic cholinergic activity of rat superior cervical ganglion. Brain Res 636:181-186
49. Klein DC, Coon SL, Roseboom PH et al (1997) The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Prog Horm Res 52:307-357
50. Vacas MI, Lowenstein P, Cardinali DP (1980) Dihydroergocryptine binding sites in bovine and rat pineal glands. J Auton Nerv Syst 2:305-313
51. Ho AK, Chik CL, Klein DC (1987) Protein kinase C is involved in adrenergic stimulation of pineal cGMP accumulation. J Biol Chem 262:10059-10064
52. Armstrong SM, Redman JR (1991) Melatonin: a chronobiotic with anti-aging properties? Med Hypotheses 34:300-309
53. Dawson D, Armstrong SM (1996) Chronobiotics-drugs that shift rhythms. Pharmacol Ther 69:15-36
54. Pevet P, Bothorel B, Slotten H, Saboureau M (2002) The chronobiotic properties of melatonin. Cell Tissue Res 309:183-191
55. Dijk DJ, Cajochen C (1997) Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms 12:627-635
56. Zhdanova IV, Tucci V (2003) Melatonin, circadian rhythms, and sleep. Curr Treat Options Neurol 5:225-229
57. Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP (2005) Melatonin and sleep in aging population. Exp Gerontol 40:911-925
58. Poeggeler B, Saarela S, Reiter RJ et al (1994) Melatonin-a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci 738:419-420
59. Barlow-Walden LR, Reiter RJ, Abe M et al (1995) Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 26:497-502
60. Urata Y, Honma S, Goto S et al (1999) Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 27:838-847
61. Mayo JC, Sainz RM, Antoli I, Herrera F, Martin V, Rodriguez C (2002) Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 59:1706-1713
62. Rodriguez C, Mayo JC, Sainz RM et al (2004) Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 36:1-9
63. Srinivasan V (2002) Melatonin oxidative stress and neurodegenerative diseases. Indian J Exp Biol 40:668-679
64. Srinivasan V, Pandi-Perumal SR, Poeggeler B, Hardeland R (2006) Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct 2:15
65. Karbownik M, Tan DX, Reiter RJ (2000) Melatonin reduces the oxidation of nuclear DNA and membrane lipids induced by the carcinogen delta-aminolevulinic acid. Int J Cancer 88:7-11
66. Vijayalaxmi, Reiter RJ, Tan DX, Herman TS, Thomas CR Jr. (2004) Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 59:639-653
67. Maestroni GJ (2001) The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 10:467-476
68. Srinivasan V, Maestroni GJM, Cardinali DP, Esquifino AI, Pandi-Perumal SR, Miller SC (2005) Melatonin, immune function and aging. Immun Ageing 2:17
69. Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJM (2006) The role of melatonin in immunoenhancement: potential application in cancer. Int J Exp Pathol 87:81-87
70. Vijayalaxmi, Thomas CR Jr., Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575-2601
71. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ (2001) Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 22:45-47
72. Cui P, Luo Z, Zhang H et al (2006) Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J Pineal Res 41:358-362
73. Kajdaniuk D, Marek B, Kos-Kudla B et al (2002) Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-I concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defense? Med Sci Monit 8:CR457-CR461
74. Bulbuller N, Dogru O, Yekeler H, Cetinkaya Z, Ilhan N, Kirkil C (2005) Effect of melatonin on wound healing in normal and pinealectomized rats. J Surg Res 123:3-7
75. Soybir G, Topuzlu C, Odabas O, Dolay K, Bilir A, Koksoy F (2003) The effects of melatonin on angiogenesis and wound healing. Surg Today 33:896-901
76. Ram PT, Dai J, Yuan L et al (2002) Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 179:141-150
77. Nosjean O, Ferro M, Coge F et al (2000) Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 275:31311-31317
78. Wiesenberg I, Missbach M, Kahlen JP, Schrader M, Carlberg C (1995) Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 23:327-333
79. Schaeren-Wiemers N, Andre E, Kapfhammer JP, Becker-Andre M (1997) The expression pattern of the orphan nuclear receptor RORbeta in the developing and adult rat nervous system suggests a role in the processing of sensory information and in circadian rhythm. Eur J Neurosci 9:2687-2701
80. Dai J, Ram PT, Yuan L, Spriggs LL, Hill SM (2001) Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin. Mol Cell Endocrinol 176:111-120
81. Reppert SM, Weaver DR, Ebisawa T (1994) Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 13:1177-1185
82. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP (1980) Light suppresses melatonin secretion in humans. Science 210:1267-1269
83. Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557-1562
84. Schernhammer ES, Laden F, Speizer FE et al (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 93:1563-1568
85. Hansen J (2001) Light at night, shiftwork, and breast cancer risk. J Natl Cancer Inst 93:1513-1515
86. Hansen J (2006) Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control 17:531-537
87. Hahn RA (1991) Profound bilateral blindness and the incidence of breast cancer. Epidemiology 2:208-210
88. Feychting M, Osterlund B, Ahlbom A (1998) Reduced cancer incidence among the blind. Epidemiology 9:490-494
89. Kliukiene J, Tynes T, Andersen A (2001) Risk of breast cancer among Norwegian women with visual impairment. Br J Cancer 84:397-399
90. Pukkala E, Ojamo M, Rudanko SL, Stevens RG, Verkasalo PK (2006) Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment. Cancer Causes Control 17:573-576
91. Dauchy RT, Sauer LA, Blask DE, Vaughan GM (1997) Light contamination during the dark phase in "photoperiodically controlled" animal rooms: effect on tumor growth and metabolism in rats. Lab Anim Sci 47:511-518
92. Dauchy RT, Blask DE, Sauer LA, Brainard GC, Krause JA (1999) Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Lett 144:131-136
93. Blask DE, Brainard GC, Dauchy RT et al (2005) Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 65:11174-11184
94. Figueiro MG, Rea MS, Bullough JD (2006) Circadian effectiveness of two polychromatic lights in suppressing human nocturnal melatonin. Neurosci Lett 406:293-297
95. Hebert M, Martin SK, Lee C, Eastman CI (2002) The effects of prior light history on the suppression of melatonin by light in humans. J Pineal Res 33:198-203
96. Smith KA, Schoen MW, Czeisler CA (2004) Adaptation of human pineal melatonin suppression by recent photic history. J Clin Endocrinol Metab 89:3610-3614
97. Figueiro MG, Rea MS, Bullough JD (2006) Does architectural lighting contribute to breast cancer? J Carcinog 5:20
98. Butler GC, Nicholas J, Lackland DT, Friedberg W (2000) Perspectives of those impacted: airline pilot's perspective. Health Phys 79:602-607
99. Lim MK (2002) Cosmic rays: are air crew at risk? Occup Environ Med 59:428-432
100. Sigurdson AJ, Ron E (2004) Cosmic radiation exposure and cancer risk among flight crew. Cancer Invest 22:743-761
101. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES (2005) Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 41:2023-2032
102. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B (1981) Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a) anthracene-induced mammary tumors in the rat. Cancer Res 41:4432-4436
103. Chang N, Spaulding TS, Tseng MT (1985) Inhibitory effects of superior cervical ganglionectomy on dimethylbenz(a)anthracene-induced mammary tumors in the rat. J Pineal Res 2:331-340
104. Blask DE, Pelletier DB, Hill SM et al (1991) Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117:526-532
105. Subramanian A, Kothari L (1991) Melatonin, a suppressor of spontaneous murine mammary tumors. J Pineal Res 10:136-140
106. Cos S, Sanchez-Barcelo EJ (2000) Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 15:637-647
107. Rao GN, Ney E, Herbert RA (2000) Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res Treat 64:287-296
108. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ (2006) Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11:857-867
109. Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29-36
110. Karasek M, Marek K, Zielinska A, Swietoslawski J, Bartsch H, Bartsch C (1994) Serial transplants of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Fischer rats as model system for human breast cancer. 3. Quantitative ultrastructural studies of the pinealocytes and plasma melatonin concentrations in rats bearing an advanced passage of the tumor. Biol Signals 3:302-306
111. Blask DE (2001) An overview of the neuroendocrine regulation of experimental tumor growth by melatonin and its analogues and the therapeutic use of melatonin in oncology. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D (eds) The pineal gland and cancer: neuroimmunoendocrine mechanisms in malignancy. Springer, Berlin, pp. 309-342
112. Edwards DP, Chamness GC, McGuire WL (1979) Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta 560:457-486
113. Dickson RB, Lippman ME (1987) Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8:29-43
114. Dubik D, Shiu RP (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263:12705-12708
115. Weisz A, Bresciani F (1988) Estrogen induces expression of c-fos and c-myc protooncogenes in rat uterus. Mol Endocrinol 2:816-824
116. Molis TM, Spriggs LL, Jupiter Y, Hill SM (1995) Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res 18:93-103
117. Ram PT, Kiefer T, Silverman M, Song Y, Brown GM, Hill SM (1998) Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. Mol Cell Endocrinol 141:53-64
118. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM (2002) MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 192:147-156
119. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS (1994) Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458-4466
120. Kato S, Endoh H, Masuhiro Y et al (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
121. Pujol P, Rey JM, Nirde P et al (1998) Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367-5373
122. Molis TM, Spriggs LL, Hill SM (1994) Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8:1681-1690
123. Kiefer T, Ram PT, Yuan L, Hill SM (2002) Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 71:37-45
124. Benitez-King G, Huerto-Delgadillo L, Anton-Tay F (1991) Melatonin modifies calmodulin cell levels in MDCK and N1E-115 cell lines and inhibits phosphodiesterase activity in vitro. Brain Res 557:289-292
125. Romero MP, Garcia-Perganeda A, Guerrero JM, Osuna C (1998) Membrane-bound calmodulin in Xenopus laevis oocytes as a novel binding site for melatonin. FASEB J 12:1401-1408
126. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S (1999) Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13:857-868
127. Garcia Pedrero JM, Del Rio B, Martinez-Campa C, Muramatsu M, Lazo PS, Ramos S (2002) Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol 16:947-960
128. del Rio B, Garcia Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS, Ramos S (2004) Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 279:38294-38302
129. Blask DE (1998) The melatonin rhythm in cancer patients. In: Shaffi M, Shaffi SL (eds) Melatonin in psychiatric and neoplastic disorders. American Psychiatric Press Inc., Washington DC, pp. 243-260
130. Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L (1981) Urinary melatonin levels in human breast cancer patients. J Neural Transm 52:281-294
131. Tamarkin L, Danforth D, Lichter A et al (1982) Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 216:1003-1005
132. Bartsch C, Bartsch H, Bellmann O, Lippert TH (1991) Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 67:1681-1684
133. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D (1989) Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer 64:426-433
134. Maestroni GJM, Conti A (1996). Melatonin in human breast cancer tissue: Association with nuclear grade and estrogen receptor status. Lab Inv 75:557-561
135. Skene DJ, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J (1990) 6-sulphatoxymelatonin production in breast cancer patients. J Pineal Res 8:269-276
136. Carlson LE, Campbell TS, Garland SN, Grossman P (2007) Associations among Salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and healthy controls. J Behav Med 30:45-58
137. Smith JE, Richardson J, Hoffman C, Pilkington K (2005) Mindfulness-Based Stress Reduction as supportive therapy in cancer care: systematic review. J Adv Nurs 52:315-327
138. Shapiro SL, Bootzin RR, Figueredo AJ, Lopez AM, Schwartz GE (2003) The efficacy of mindfulness-based stress reduction in the treatment of sleep disturbance in women with breast cancer: an exploratory study. J Psychosom Res 54:85-91
139. Kreitzer MJ, Gross CR, Ye X, Russas V, Treesak C (2005) Longitudinal impact of mindfulness meditation on illness burden in solid-organ transplant recipients. Prog Transplant 15:166-172
140. Massion AO, Teas J, Hebert JR, Wertheimer MD, Kabat-Zinn J (1995) Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. Med Hypotheses 44:39-46
141. Harinath K, Malhotra AS, Pal K et al (2004) Effects of Hatha yoga and Omkar meditation on cardiorespiratory performance, psychologic profile, and melatonin secretion. J Altern Complement Med 10:261-268
142. Carlson LE, Speca M, Patel KD, Goodey E (2003) Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom Med 65:571-581
143. Verkasalo PK, Lillberg K, Stevens RG et al (2005) Sleep duration and breast cancer: a prospective cohort study. Cancer Res 65:9595-9600
144. Tonini G, Nunziata C, Prete SP et al (1998) Adjuvant treatment of breast cancer: a pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha. Cancer Immunol Immunother 47:157-166
145. Carlson LE, Speca M, Patel KD, Goodey E (2004) Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 29:448-474